|
|
|
|
|
Advances in Treatment of Triple Negative Breast Cancer |
| KANG Yikun, YUAN Peng |
| Department of VIP Medical Services, National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China |
|
|
|
|
Abstract TNBC is a special type of breast cancer with strong aggressiveness and poor prognosis. Chemotherapy is still the main treatment for TNBC, due to poor efficacy of endocrine therapy and targeted therapy. However, TNBC is a kind of heterogeneous disease, so it is urgent to study the precise molecular types and explore new precision treatment. This paper will summarize the results of clinical trials and analyze treatment strategies for TNBC, including surgical treatment, radiotherapy, chemotherapy, targeted therapy and immunotherapy, in order to provide evidence for clinical management.
|
| Keywords
TNBC
BRCA gene
Chemotherapy
Immunotherapy
|
|
|
| Fund:National Natural Science Foundation of China (No. 81672634, 82172650); Beijing Medical Award Foundation (No. YXJL-2020-0941-0763); Beijing Natural Science Foundation (No. 7222150) |
|
Issue Date: 11 August 2022
|
|
[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020[J]. CA
Cancer J Clin, 2020, 70(1): 7-30.
[2] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):
209-249.
[3] Torre LA, Islami F, Siegel RL, et al. Global Cancer in Women:
Burden and Trends[J]. Cancer Epidemiol Biomarkers Prev, 2017,
26(4): 444-457.
[4] Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast
cancer: clinical features and patterns of recurrence[J]. Clin Cancer
Res, 2007, 13(15 Pt 1): 4429-4434.
[5] Coughlin SS. Epidemiology of Breast Cancer in Women[J]. Adv
Exp Med Biol, 2019, 1152: 9-29.
[6] van Maaren MC, de Munck L, de Bock GH, et al. 10 year survival
after breast-conserving surgery plus radiotherapy compared
with mastectomy in early breast cancer in the Netherlands: a
population-based study[J]. Lancet Oncol, 2016, 17(8): 1158-1170.
[7] Abdulkarim BS, Cuartero J, Hanson J, et al. Increased risk of
locoregional recurrence for women with T1-2N0 triplenegative
breast cancer treated with modified radical mastectomy without
adjuvant radiation therapy compared with breast-conserving
therapy[J]. J Clin Oncol, 2011, 29(21): 2852-2858.
[8] Chen QX, Wang XX, Lin PY, et al. The different outcomes between breast-conserving surgery and mastectomy in triplenegative
breast cancer: a population-based study from the SEER
18 database[J]. Oncotarget, 2017, 8(3): 4773-4780.
[9] Haffty BG, Yang Q, Reiss M, et al. Locoregional relapse and
distant metastasis in conservatively managed triple negative earlystage
breast cancer[J]. J Clin Oncol, 2006, 24(36): 5652-5657.
[10]Keam B, Im SA, Kim HJ, et al. Prognostic impact of
clinicopathologic parameters in stage Ⅱ/Ⅲ breast cancer treated
with neoadjuvant docetaxel and doxorubicin chemotherapy:
paradoxical features of the triple negative breast cancer[J]. BMC
Cancer, 2007, 7: 203.
[11] Untch M, Jackisch C, Schneeweiss A, et al. Nab-paclitaxel versus
solvent-based paclitaxel in neoadjuvant chemotherapy for early
breast cancer (GeparSepto-GBG 69): A randomised, phase 3
trial[J]. Lancet Oncol, 2016, 17(3): 345-356.
[12] Gianni L, Mansutti M, Anton A, et al. Comparing Neoadjuvant
Nabpaclitaxel vs Paclitaxel Both Followed by Anthracycline
Regimens in Women With ERBB2/HER2-Negative Breast
Cancer-The Evaluating Treatment With Neoadjuvant Abraxane
(ETNA) Trial: A Randomized Phase 3 Clinical Trial[J]. JAMA
Oncol, 2018, 4(3): 302-308.
[13] Sikov WM, Berry DA, Perou CM, et al. Impact of the addition
of carboplatin and/or bevacizumab to neoadjuvant once-perweek
paclitaxel followed by dose-dense doxorubicin and
cyclophosphamide on pathologic complete response rates in stage
Ⅱ to Ⅲ triple-negative breast cancer: cALGB 40603 (Alliance)[J].
J Clin Oncol, 2015, 33(1): 13-21.
[14] Zhang P, Yin Y, Mo H, et al. Better pathologic complete response
and relapse-free survival after carboplatin plus paclitaxel
compared with epirubicin plus paclitaxel as neoadjuvant
chemotherapy for locally advanced triple-negative breast
cancer: a randomized phase 2 trial[J]. Oncotarget, 2016, 7(37):
60647-60656.
[15] Alba E, Chacon JI, Lluch A, et al. A randomized phaseⅡ trial
of platinum salts in basal-like breast cancer patients in the
neoadjuvant setting. Results from the GEICAM/2006-03,
multicenter study[J]. Breast Cancer Res Treat, 2012, 136(2):
487-493.
[16] Byrski T, Huzarski T, Dent R, et al. Pathologic complete response
to neoadjuvant cisplatin in BRCA1-positive breast cancer
patients[J]. Breast Cancer Res Treat, 2014, 147(2): 401-405.
[17] Hahnen E, Lederer B, Hauke J, et al. Germline Mutation Status,
Pathological Complete Response, and Disease-Free Survival
in Triple-Negative Breast Cancer: Secondary Analysis of the
GeparSixto Randomized Clinical Trial[J]. JAMA Oncol, 2017,
3(10): 1378-1385.
[18] Mackey JR, Pieńkowski T, Crown J, et al. Long-term outcomes
after adjuvant treatment of sequential versus combination
docetaxel with doxorubicin and cyclophosphamide in nodepositive
breast cancer: BCIRG-005 randomized trial[J]. Ann
Oncol, 2016, 27(6): 1041-1047.
[19] Wang X, Wang SS, Huang H, et al. Effect of Capecitabine
Maintenance Therapy Using Lower Dosage and Higher Frequency
vs Observation on Disease-Free Survival Among Patients With
Early-Stage Triple-Negative Breast Cancer Who Had Received
Standard Treatment: The SYSUCC-001 Randomized Clinical
Trial[J]. JAMA, 2021, 325(1): 50-58.
[20] Tutt ANJ, Garber JE, Kaufman B, et al. Adjuvant Olaparib for
Patients with BRCA1- or BRCA2-Mutated Breast Cancer[J]. N
Engl J Med, 2021, 384(25): 2394-2405.
[21] Isakoff SJ, Mayer EL, He L, et al. TBCRC009: A Multicenter
PhaseⅡ Clinical Trial of Platinum Monotherapy With Biomarker
Assessment in Metastatic Triple-Negative Breast Cancer[J]. J Clin
Oncol, 2015, 33(17): 1902-1909.
[22] Yardley DA, Coleman R, Conte P, et al. nab-Paclitaxel plus
carboplatin or gemcitabine versus gemcitabine plus carboplatin
as first-line treatment of patients with triple-negative metastatic
breast cancer: results from the tnAcity trial[J]. Ann Oncol, 2018,
29(8): 1763-1770.
[23] Tutt A, Tovey H, Cheang MCU, et al. Carboplatin in BRCA1/2-
mutated and triple-negative breast cancer BRCAness subgroups:
the TNT Trial[J]. Nat Med, 2018, 24(5): 628-637.
[24] Hu XC, Zhang J, Xu BH, et al. Cisplatin plus gemcitabine versus
paclitaxel plus gemcitabine as first-line therapy for metastatic
triple-negative breast cancer (CBCSG006): a randomised, openlabel,
multicentre, phase 3 trial[J]. Lancet Oncol, 2015, 16(4):
436-646.
[25] Wang Z, Xu L, Wang H, et al. Lobaplatin-based regimens
outperform cisplatin for metastatic breast cancer after
anthracyclines and taxanes treatment[J]. Saudi J Biol Sci, 2018,
25(5): 909-916.
[26] Yuan P, Hu X, Sun T, et al. Eribulin mesilate versus vinorelbine
in women with locally recurrent or metastatic breast cancer: A
randomised clinical trial[J]. Eur J Cancer, 2019, 112: 57-65.
[27] Zhang P, Sun T, Zhang Q, et al. Utidelone plus capecitabine versus
capecitabine alone for heavily pretreated metastatic breast cancer
refractory to anthracyclines and taxanes: a multicentre, openlabel,
superiority, phase 3, randomised controlled trial[J]. Lancet
Oncol, 2017, 18(3): 371-383.
[28] Robson M, Im SA, Senkus E, et al. Olaparib for Metastatic Breast
Cancer in Patients with a Germline BRCA Mutation[J]. N Engl J
Med, 2017, 377(6): 523-533.
[29] Robson ME, Tung N, Conte P, et al. OlympiAD final overall
survival and tolerability results: Olaparib versus chemotherapy
treatment of physician's choice in patients with a germline BRCA
mutation and HER2-negative metastatic breast cancer[J]. Ann
Oncol, 2019, 30(4): 558-566.
[30] Litton JK, Rugo HS, Ettl J, et al. Talazoparib in patients with
advanced breast cancer with a germline BRCA mutation[J]. N
Engl J Med, 2018, 379(8): 753-763.
[31] O’Shaughnessy J, Osborne C, Pippen JE, et al. Iniparib plus
chemotherapy in metastatic triple-negative breast cancer[J]. N Engl J Med, 2011, 364(3): 205-214.
[32] O’Shaughnessy J, Sehwartzberg L, Danso MA, et al. Phase
III study of iniparib plus gemcitabine and carboplatin versus
gemeitabine and carboplatin in patients with metastatic triplenegative
breast cancer[J]. J Clin Oncol, 2014, 32(34): 3840-3847.
[33] Kalinsky K, Diamond JR, Vahdat LT, et al. Sacituzumab govitecan
in previously treated hormone receptor-positive/HER2-negative
metastatic breast cancer: final results from a phase Ⅰ/Ⅱ, singlearm,
basket trial[J]. Ann Oncol, 2020, 31(12): 1709-1718.
[34] Son S, Shin S, Rao NV, et al. Anti-Trop2 antibody-conjugated
bioreducible nanoparticles for targeted triple negative breast
cancer therapy[J]. Int J Biol Macromol, 2018, 110: 406-415.
[35] Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab Govitecan
in Metastatic Triple-Negative Breast Cancer[J]. N Engl J Med,
2021, 384(16): 1529-1541.
[36] Nagayama A, Vidula N, Ellisen L, et al. Novel antibody-drug
conjugates for triple negative breast cancer[J]. Ther Adv Med
Oncol, 2020, 12: 1758835920915980.
[37] Robert NJ, Die′ras V, Glaspy J, et al. RIBBON-1: randomized,
double-blind, placebo-controlled, phase Ⅲ trial of chemotherapy
with or without bevacizumab for first-line treatment of human
epidermal growth factor receptor 2-negative, locally recurrent or
metastatic breast cancer[J]. J Clin Oncol, 2011, 29(10): 1252-1260.
[38] Brufsky A, Valero V, Tiangco B, et al. Second-line bevacizumabcontaining
therapy in patients with triple-negative breast cancer:
subgroup analysis of the RIBBON-2 trial[J]. Breast Cancer Res
Treat, 2012, 133(3): 1067-1075.
[39] von Minckwitz G, Schneeweiss A, Loibl S, et al. Neoadjuvant
carboplatin in patients with triple-negative and HER2-positive
early breast cancer (GeparSixto; GBG 66): a randomised phase 2
trial[J]. Lancet Oncol, 2014, 15(7): 747-756.
[40] Gerber B, Loibl S, Eidtmann H, et al. Neoadjuvant bevacizumab
and anthracycline–taxane-based chemotherapy in 678 triplenegative
primary breast cancers; results from the geparquinto
study (GBG 44)[J]. Ann Oncol, 2013, 24(12): 2978-2984.
[41] Bear HD, Tang G, Rastogi P, et al. Bevacizumab added to
neoadjuvant chemotherapy for breast cancer[J]. N Engl J Med,
2012, 366(4): 310-320.
[42] Lyons TG. Targeted Therapies for Triple-Negative Breast
Cancer[J]. Curr Treat Options Oncol, 2019, 20(11): 82.
[43] Adams S, Loi S, Toppmeyer D, et al. Pembrolizumab monotherapy
for previously untreated, PD-L1-positive, metastatic triplenegative
breast cancer: cohort B of the phase Ⅱ KEYNOTE-086
study[J]. Ann Oncol, 2019, 30(3): 405-411.
[44] Adams S, Schmid P, Rugo HS, et al. Pembrolizumab monotherapy
for previously treated metastatic triple-negative breast cancer:
cohort A of the phaseⅡ KEYNOTE-086 study[J]. Ann Oncol,
2019, 30(3): 397-404.
[45] Schmid P, Adams S, Rugo HS, et al. Atezolizumab and Nab-
Paclitaxel in Advanced Triple-Negative Breast Cancer[J]. N Engl
J Med, 2018, 379(22): 2108-2121.
[46] Schmid P, Rugo HS, Adams S, et al. Atezolizumab plus nabpaclitaxel
as first-line treatment for unresectable, locally advanced
or metastatic triple-negative breast cancer (IMpassion130):
updated efficacy results from a randomised, double-blind,
placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2020, 21(1):
44-59.
[47] Cortes J, Cescon DW, Rugo HS, et al. Pembrolizumab plus
chemotherapy versus placebo plus chemotherapy for previously
untreated locally recurrent inoperable or metastatic triplenegative
breast cancer (KEYNOTE-355): a randomised, placebocontrolled,
double-blind, phase 3 clinical trial[J]. Lancet, 2020,
396(10265): 1817-1828.
[48] Jiang YZ, Liu Y, Xiao Y, et al. Molecular subtyping and genomic
profiling expand precision medicine in refractory metastatic triplenegative
breast cancer: the FUTURE trial[J]. Cell Res, 2021,
31(2): 178-186.
[49] Schmid P, Cortes J, Pusztai L, et al. KEYNOTE-522 Investigators.
Pembrolizumab for Early Triple-Negative Breast Cancer[J]. N
Engl J Med, 2020, 382(9): 810-821.
[50] Mittendorf EA, Zhang H, Barrios CH, et al. Neoadjuvant
atezolizumab in combination with sequential nab-paclitaxel
and anthracycline-based chemotherapy versus placebo and
chemotherapy in patients with early-stage triple-negative breast
cancer (IMpassion031): a randomised, double-blind, phase 3
trial[J]. Lancet, 2020, 396(10257): 1090-1100.
[51] Nanda R, Liu MC, Yau C, et al. Effect of Pembrolizumab Plus
Neoadjuvant Chemotherapy on Pathologic Complete Response
in Women With Early-Stage Breast Cancer: An Analysis of the
Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial[J]. JAMA
Oncol, 2020, 6(5): 676-684.
[52] Gianni L, Huang CS, Egle D, et al. Pathologic complete response
(pCR) to neoadjuvant treatment with or without atezolizumab in
triple-negative, early high-risk and locally advanced breast cancer:
NeoTRIP Michelangelo randomized study[J]. Ann Oncol, 2022,
33(5): 534-543.
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
